Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.

Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 years, or enrollment in clinical trials.

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure No significant conflicts of interests to disclose. Dr S.V. Rajkumar reports grants from NIH, United States outside the submitted work. Dr S. Kumar reports consultancy from BMS/Celgene, Takeda, United States, and Janssen, United States, and research funding from BMS, United States/Celgene, Takeda, Novartis, Switzerland, AbbVie, Janssen, and Amgen, United States. Dr L. Bergsagel reports grants from the NCI, United States, research funding from Pfizer, United States, consultancy for Pfizer, and AbbVie.